IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4179
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$7M
David P. Luci
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ACXP Acurx Pharmaceuticals, Inc. | 34 | 20 | 3 | 48 | - | - | -253.2% | -150.8% | - | - | - | - | 0.0% | 68.0x | $7M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Acurx Pharmaceuticals, Inc. (ACXP) receives a "Avoid" rating with a composite score of 34.3/100. It ranks #4179 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ACXP.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 20 | 3 | +17ALPHA |
| MOMENTUM | 48 | 41 | +7ALPHA |
| VALUATION | 3 | 1 | +2NEUTRAL |
| INVESTMENT | 37 | 68 | -31DRAG |
| STABILITY | 36 | 23 | +13ALPHA |
| SHORT INT | 78 | 88 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -253.2% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Acurx Pharmaceuticals, Inc. (ACXP) as Avoid with a composite score of 34.3/100 at a current price of $1.59. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Acurx Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.3/100 places it at rank #4179 in our full universe.
No Moat
Medium
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Acurx Pharmaceuticals, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Acurx Pharmaceuticals, Inc. with an Avoid rating, assigning a composite score of 34.3/100 and 1 out of 5 stars. Ranked #4179 of 7,333 stocks, ACXP falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Acurx Pharmaceuticals, Inc. registers a weak quality score of just 20/100, indicating significant profitability challenges. The company reports a return on equity of -253.2% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
ACXP registers a value score of just 3/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.16x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Acurx Pharmaceuticals, Inc.'s investment score of 37/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -150.8% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ACXP is currently showing below-average momentum at 48/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of -1.86 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ACXP's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -1.86 and a debt-to-equity ratio of 68.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
ACXP carries a short interest score of 78/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 68.00x), micro-cap liquidity risk. At $7M market cap (micro-cap), Acurx Pharmaceuticals, Inc. offers reasonable institutional liquidity.
Acurx Pharmaceuticals, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4179 of 7,333 overall (43rd percentile). Key comparisons include ROE of -253.2% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ACXP currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (3) would have the largest impact on the composite score.
ROE 13227% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 32281% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open.
With the business potentially at an important milestone, we thought we'd take a closer look at Acurx Pharmaceuticals...

Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of 81 cents per share, according to data from Benzinga Pro. Alcoa still sees full-year alumina production of between 9.8 million and 10 million metric tons and full-year alumina shipments between 12.7 million and 12.9 million metric tons. Alcoa shares jumped 3% to $36.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) shares gained 155.6% to $1.24 in pre-market trading after gaining around 8% on Wednesday. MicroCloud Hologram Inc. (NASDAQ: HOLO) gained 51.8% to $3.40 in pre-market trading after falling around 5% on Wednesday. Smart for Life, Inc. (NASDAQ: SMFL) shares gained 28.4% to $0.6035 in pre-market trading after gaining over 21% on Wednesday. Tantech Holdings ...

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Treasure Global Inc. (NASDAQ: TGL) gained 31% to $0.1144. LQR House Inc. (NASDAQ: LQR) gained 30.4% to $2.6344 after dipping 45% on Tuesday. LQR House announced an increase of its share buyback program to $5 million. ProQR Therapeutics N.V. (NASDAQ: PRQR) rose 29% to $3.2123. Safety Shot, Inc. (NASDAQ: SHOT) climbed 26.7% to $2.2692. Safety Shot responded to FSD Pharma's unauthorized tagging of its stock and making false claims in an effort to harm the company and its shareholders. Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) gained 27% to $3.3626 after the company reported early results from its collaboration with Lieber Institute for Brain Development (LIBD). Fitell Corporation (NASDAQ: FTEL) rose 25.7% to $1.2451. Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares climbed 25.6% to $0.1594 after falling more than 9% on Tuesday. Cognition Therapeutics, Inc. (NASDAQ: CGTX) gained 22.4% to $2.5339. Rail Vision Ltd. (NASDAQ: RVSN) rose 22% to $2.0510 as the company said that a leading US-based rail and leasing services company signed a supply contract with Rail Vision valued at up to $5,000,000 for the purchase of Rail Vision’s AI-based Switch Yard Systems. Digital World Acquisition Corp. (NASDAQ: DWAC) jumped 17.5% to $26.25 after Donald Trump recently won the Iowa GOP caucus. Digital World Acquisition Corp is the business combination partner of Trump Media & Technology Group. American Coastal Insurance Corporation ...

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp. Bluegreen Vacations Holding Corporation (NYSE: BVH) gained 105.8% to $73.11 after the company announced it would be acquired by Hilton Grand Vacations at $75 per share. Verb Technology Company, Inc. (NASDAQ: VERB) shares climbed 59.5% to $0.4086 amid the company announcing new technology integrations for its MARKET.live platform. MSP Recovery, Inc. (NASDAQ: LIFW) jumped 34.7% to $3.69. Digital Brands Group, Inc. (NASDAQ: DBGI) shares gained 34.3% to $5.87 after the company announced review of strategic alternatives. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) jumped 32.7% to $0.4971. Organigram Holdings Inc. (NASDAQ: OGI) gained 28.8% to $1.48 after the company announced a C$124.6 million investment from BAT and the creation of "Jupiter" strategic investment pool. Cheetah Net Supply Chain Service Inc. (NASDAQ: CTNT) rose 26% to $1.45. Celldex Therapeutics, Inc. (NASDAQ: CLDX) gained 23.5% to $32.09 after the company announced data from its phase 2 trial treating urticaria refractory. RiskOn International, Inc. (NASDAQ: ROI) climbed 23.2% to $0.8499. Napco Security Technologies, Inc. (NASDAQ: NSSC) surged 20.8% to $22.72 following strong quarterly sales. Freshpet, Inc. (NASDAQ: FRPT) gained 20.2% to $69.99. Freshpet reported third-quarter FY23 sales growth of 32.6% year-on-year to $200.60 million, beating the analyst consensus estimate of $194.11 million. reAlpha Tech Corp. (NASDAQ: AIRE) gained 20% to $10.79. PainReform Ltd. (NASDAQ: PRFX) climbed 18.7% to $2.79 Indaptus Therapeutics, Inc. (NASDAQ: